Osteoporotic vertebral fractures during pregnancy: Be aware of a potential underlying genetic cause

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1107-1111

  Campos Obando, Natalia ^a   Oei, Ling ^a   Hoefsloot, Lies H ^b   Kiewiet, Rosalie M ^c   Klaver, Caroline C W ^a   Simon, Marleen E H ^a   Carola Zillikens, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; HUMANS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PEDIGREE; PREGNANCY; PREGNANCY COMPLICATIONS; SPINAL FRACTURES; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84898437362     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3238     Document Type: Article

References (28)

1. Nordin BE, Roper A. Post-pregnancy osteoporosis; a syndrome? Lancet. 1955;268:431-434.
2. Choe EY, Song JE, Park KH, et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab. 2012;30:596-601.
3. O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006;17:1008-1012.
4. Sowers MF, Hollis BW, Shapiro B, et al. Elevated parathyroid hormone-related peptide associated with lactation and bone density loss. JAMA. 1996;276:549-554.
5. Maliha G, Morgan J, Vrahas M. Transient osteoporosis of pregnancy. Injury. 2012;43:1237-1241.
6. van Dijk FS, Dalgleish R, Malfait F, et al. Clinical utility gene card for: osteogenesis imperfecta. Eur J Hum Genet. doi:10.1038/ ejhg.2012.210.
7. Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, Papaio-annou NA. Case report: teriparatide treatment in a case of severe pregnancy-and lactation-associated osteoporosis. Hormones (Athens). 2012;11:495-500.
8. Kovacs CS. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinol Metab Clin North Am. 2011;40:795-826.
9. Dunne F, Walters B, Marshall T, Heath DA. Pregnancy associated osteoporosis. Clin Endocrinol (Oxf) . 1993;39:487-490.
10. Carbone LD, Palmieri GM, Graves SC, Smull K. Osteoporosis of pregnancy: long-term follow-up of patients and their offspring. Ob-stet Gynecol. 1995;86:664-666.
11. Ai M, Heeger S, Bartels CF, Schelling DK. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005;77:741-753.
12. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107: 513-523.
13. Nikopoulos K, Venselaar H, Collin RW, et al. Overview of the mutation spectrum in familial exudative vitreoretinopathy and Nor-rie disease with identification of 21 novel variants in FZD4, LRP5,and NDP. Hum Mutat. 2010;31:656-666.
14. Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H. Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum Mutat. 2005;26:104-112.
15. Tuysiiz B, Bursali A, Alp Z, Suyugul N, Laine CM, Makitie O. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment. Horm Res Paediatr. 2012;77:115-120.
16. Gong Y, Vikkula M, Boon L, et al. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet. 1996; 59:146-151.
17. Somer H, Palotie A, Somer M, Hoikka V, Peltonen L. Osteoporosis- pseudoglioma syndrome: clinical, morphological, and biochemical studies. J Med Genet. 1988;25:543-549.
18. Downey LM, Bottomley HM, Sheridan E, et al. Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5. Br J Ophthalmol. 2006;90:1163-1167.
19. Laine CM, Chung BD, Susic M, et al. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet. 2011;19:875-881.
20. Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res. 2005;20:783-789.
21. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491-501.
22. Chan B, Zacharin M. Maternal and infant outcome after pamidro-nate treatment of polyostotic fibrous dysplasia and osteogenesis im-perfecta before conception: a report of four cases. J Clin Endocrinol Metab. 2006;91:2017-2020.
23. Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bispho-sphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10:280-291.
24. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hy-droxyapatite. Bone. 2006;38:617-627.
25. Peris P, Torra M, Olivares V, et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone. 2011;49:706-709.
26. Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. NEngl J Med. 2013;368:1809-1816.
27. Styrkarsdottir U, Thorleifsson G, Sulem P, et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature. 2013;497:517-520.
28. van Dijk FS, Zillikens MC, Micha D, et al. PLS3 mutations in X-linked osteoporosis with fractures. N Engl JMed. 2013;369:1529-1536.